America’s nationally-based prostate cancer organizations have developed a shared, national policy agenda — in the interests of the hundreds of thousands of American men who are at risk each year for a diagnosis of prostate cancer and more than 2 million men living today who have been diagnosed with this highly prevalent form of cancer.
Click here to print a copy of the Policy Agenda to distribute to your members and supporters, and to share with policy makers and elected officials.
Prostate Cancer Policy Agenda – 2015 – 2016
- We continue to seek an appropriations increase to support the successful research activities of the Prostate Cancer Research Program within the Department of Defense’s Congressionally Directed Medical Research Program – from its current $80 million to $120 million per year.
- We join with the broader cancer community to support increased federal appropriations for cancer research for the National Institutes of Health, the National Cancer Institute, and the Centers for Disease Control and Prevention.
- We support an increase to $400 million per year from the current funding level of $288 million for basic and translational prostate cancer research at the National Cancer Institute.
- We seek passage of a bill to create an Office on Men’s Health within the Department of Health and Human Services (HHS) that can mirror the successes of the Office on Women’s Health established in 1991.
- We support legislative, research, and educational efforts needed to effectively combat – and ideally to eliminate — the epidemic of prostate cancer among African American men.
- We propose the establishment of a Prostate Cancer Scientific Advisory Board for the Office of the Chief Scientist at the U.S. Food & Drug Administration (FDA), with the goal of accelerating the real-time sharing of research data and the movement of new medicines into clinical practice in the best interests of patients.
- We support revisions to the decision-making processes of the U.S. Preventive Services Task Force (USPSTF) to ensure appropriate input from representatives of patient advocacy groups, specialty medical groups, and other federal agencies that have expertise in each area of preventive services under review.
- We encourage the inclusion of quality-of-life-related endpoints, based on patient-reported outcomes data, in pivotal trials of all biologic and pharmaceutical agents being assessed for regulatory approval in the treatment of prostate cancer with a primary endpoint of improved survival — such that quality-of-life-related data (positive or negative) and survival data can be included in labeling for products indicated for treatment of prostate cancer when appropriate.
Effective January 1, 2015